Off-the-Shelf cell therapy takes on multiple myeloma
NCT ID NCT06006741
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new type of cell therapy called universal CAR-T cells for people with multiple myeloma that has not been cured by standard treatments. The therapy uses donor cells modified to target myeloma cells, aiming to be a ready-made option. The study will enroll 20 participants to check safety and how well the cells work against the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- universal CAR-T cells
- What this could lead to
- If successful, this could lead to a more accessible 'off-the-shelf' cell therapy for multiple myeloma, potentially reducing the need for personalized treatments.
- What could go wrong
- This is a very early Phase 1 trial with only 20 participants, so safety and effectiveness are not yet proven. There are risks of side effects, and the cells may not persist or work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN REMISSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-Immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China